Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
45th European Brain and Behaviour Society Meeting
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Keystone Symposium: Multiple Sclerosis
PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Regulation of prefrontal cortex myelination by the microbiota.
Incorporating Alcohol Pharmacotherapies Into Medical Practice
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Power estimation for non-standardized multisite studies.
Intas launches biosimilar version of Rituximab
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.

Pages